2023 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷) : 2023-12-15
±³À°ÀÏÀÚ : 2023-12-15
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼¿ï È£ÅÚ ±×·£µåȦ
±³À°ÁÖÁ¦ : 2023 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520
À̸ÞÀÏ : retina@retina.or.kr
±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀÎ : 380¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 24ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í »çÀüµî·Ï: Àü°ø, ÀüÀÓÀÇ 8¸¸¿ø / Àü¹®ÀÇ 10¸¸¿øÇöÀåµî·Ï: Àü°ø, ÀüÀÓÀÇ 10¸¸¿ø / Àü¹®ÀÇ 12¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:10~09:17 (ÃÊ·Ï)Crystallin alpha B as a new therapeutic target against chorioretinal diseases ¹ÎÁ¤±â(¿ï»ê´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:17~09:24 (ÃÊ·Ï)TREATEMNT OF MACULAR DEGENERATION USING HUMAN SOMATIC CELL NUCLEAR TRANSFER EMBRYONIC STEM CELL DERIVED RETINAL PIGMENT EPITHELIUM: 1-YEAR RESULTS IN AN ASIAN PATIENT ¼º¿µÁ¦(CAH´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:24~09:31 (ÃÊ·Ï)Clinical Applications of Super-resolution Microscopy: Intracellular Cytoskeleton Changes in Müller Cells after TGF-beta Application ¾çÇö½Â(¼¿ï½Å¼¼°è¾È°ú)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:31~09:38 (ÃÊ·Ï)Targeting mitochondria of senescent cells for retinal rejuvenation Á¤Çý¿ø(°Ç±¹´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:38~09:45 (ÃÊ·Ï)The Modulation of Electrical Pulse Duration Elicits Reliable Network-Mediated Responses of Retinal Ganglion Cells in Normal, Not in Degenerate Primate Retinas ±¸¿ë¼÷(ÃæºÏ´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:45~09:52 (ÃÊ·Ï)Longitudinal Changes in Molecular Features of HCN Channel Isoforms Throughout the Progression of Outer Retinal Degeneration in rd10 Mice ÀӸżø(KIST)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:52~09:59 (ÃÊ·Ï)Clinical and Multimodal Imaging Features of Choroidal Nevi ±è¹Î(¿¬¼¼´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 09:59~10:06 (ÃÊ·Ï)BRCA1/2-associated retinoblastomas À̽±Ô(¿¬¼¼´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 10:15~10:26 Artificial intelligence ÀÌÇü¿ì(°Ç±¹´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 10:26~10:37 Genetics ÁÖ±¤½Ä(¼¿ï´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 10:37~10:48 New OCT Biomarkers ±è±â¿µ(°æÈñ´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 11:10~11:33 Oil versus Endophthalmitis I-van Ho(Sydney Eye Hospital)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 11:33~11:53 Management of Refractory Macular Holes ÀÌÁÖ¿ë(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 11:53~12:13 Vitreoretinal Surgery for Pediatric Patients ±è»óÁø(¼º±Õ°ü´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 13:30~13:53 Updates on Home OCT Judy Kim(Medical College of Wisconsin)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 13:53~14:16 Neovascular AMD - Choices for Tomorrow Justus G. Garweg(Berner Augenklinik & Swiss Eye institute)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 14:16~14:41 Management of Intraocular Lymphoma À̽±Ô(¿¬¼¼´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 14:50~14:57 (ÃÊ·Ï)Factors associated with the development of exudation in treatment-naive eyes with nonexudative macular neovascularization Á¶ÇÑÁÖ(±è¾È°úº´¿ø)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 14:57~15:04 (ÃÊ·Ï)Quantified anastomotic areas of MNV associated with frequent recurrence in nAMD ±èÇüÂù(°ø¾È°úº´¿ø)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 15:04~15:11 (ÃÊ·Ï)Recurrence of nAMD after discontinuation of anti-VEGF therapy using modified T&E regimen ±è±â¿µ(°æÈñ´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 15:11~15:18 (ÃÊ·Ï)´Ü¾È ¸Á¸·Ç÷°üÁ¾Áõ½Ä¿¡¼ ¹Ý´ë¾È¿¡ Ç÷°ü½Å»ý ¾øÀÌ ³ªÅ¸³ª´Â Áöµµ¸ð¾çÀ§Ãà°ú °ü·ÃµÈ Ư¼º ±èÀçÈÖ(±è¾È°úº´¿ø)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 15:18~15:25 (ÃÊ·Ï)Ãʱ¤°¢ÀÚ°¡Çü±¤¾ÈÀúÃÔ¿µÀ» ÀÌ¿ëÇÑ Áöµµ¸ð¾çÀ§ÃàÀÇ ÁøÇà ¿¬±¸ À±Á¦¹®(¼º±Õ°ü´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 15:25~15:32 (ÃÊ·Ï)Subretinal fluid in drusenoid pigment epithelium detachment: To treat or not to treat? ±è¹Ì¸®³»(°¡Å縯´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 15:32~15:39 (ÃÊ·Ï)Retinal and Choriocapillaris Blood Flow changes by Age from Quantitative OCTA Measurement in Healthy Korean Subjects º¯Àͼö(ºÎ»ê´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 15:39~15:46 (ÃÊ·Ï)Comparison of Retinal Thickness Measurements among Four Different Optical Coherence Tomography Devices ³²±âÅÂ(Á¦ÁÖ´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 15:55~16:05 Myopia: A Major Threat to National Health ¾ÈÁöÀ±(¼¿ï´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 16:05~16:15 Can the progression to High Myopia Be Prevented?: Treatment Approaches for Pediatric Myopia Á¤½Â¾Æ(¾ÆÁÖ´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 16:15~16:25 Posterior Staphyloma: Characteristics and Clinical Implications ¹Ú°À±(ÀÎÁ¦´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 16:25~16:35 Examination of Myopic Patients at the Retina Clinic ±ÇÇÑÁ¶(ºÎ»ê´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 16:35~16:45 Long-Term, Effective, and Efficient Treatment for Myopic CNV À̹οì(°Ç¾ç´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 16:45~16:50 The Future Plans of the Myopic Degeneration Research Society Áöµ¿Çö(°¡Å縯´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:00~17:05 (ÃÊ·Ï)Deep learning approach to predict post-treatment optical coherence tomography images of age-related macular degeneration after 12 monthsDeep learning approach to predict post-treatment optical coh ÀÌÇü¿ì(°Ç±¹´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:05~17:10 (ÃÊ·Ï)Automated diagnosis of macular diseases based on OCT volume scans using 3D convolutional neural network Á¶¹üÁÖ(ÇѸ²´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:10~17:15 (ÃÊ·Ï)±Ù°Å¿¡ ±â¹ÝÇØ °ÈµÈ(evidence-empowered) ÀüÀÌÇнÀ(transfer learning)À» ÀÌ¿ëÇÑ È²¹ÝºÎ ¸Á¸·ÇϾ×ÀÇ Áø´Ü ÃÖÀº¿µ(¿¬¼¼´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:15~17:20 (ÃÊ·Ï)One AI, Two Doctors: The Impact of Task Expertise on Acceptance of an AI-Based Computer-Aided Diagnosis System in Retinal Disease Ȳ´öÁø(Çѱæ¾È°úº´¿ø)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:20~17:25 (ÃÊ·Ï)ÀΰøÁö´ÉÀÇ·á±â±â °³¹ßºÎÅÍ ½ÅÀÇ·á±â¼ú±îÁö ÀÓÇüÅÃ(Duke-NUS Medical School)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:25~17:30 (ÃÊ·Ï)Accuracy of Generative Deep Learning Model for Macular Anatomy Prediction from Optical Coherence Tomography Images in Macular Hole Surgery ±ÇÇÑÁ¶(ºÎ»ê´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:30~17:35 (ÃÊ·Ï)Development of deep ensembles for screening autism spectrum disorder and symptom severity using retinal photographs °Çö±¸(¿¬¼¼´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:35~17:40 (ÃÊ·Ï)Multimodal Deep Learning Algorithm for Detection of Kidney Disease From Retinal Images and Urinalysis ±èÁØÇü(CHA´ë)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:40~17:45 (ÃÊ·Ï)½À¼º Ȳ¹Ýº¯¼º ȯÀÚ¿¡¼ ÃʱâÄ¡·á ÈÄ Àç¹ßÇÒ °¡´É¼ºÀ» ¿¹ÃøÇÏ´Â AI ¸ðµ¨ À±¿øÅÂ(±è¾È°úº´¿ø)
±³À°½Ã°£ 12¿ù 15ÀÏ ±×·£µåȦ 17:45~17:50 (ÃÊ·Ï)Risk Factors for Development of Anti-Adalimumab Antibodies in Non-Infectious Uveitis ½Å¿ë¿î(ÇѾç´ë)